Clinical Trial DRUG AG120-C-001
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
- Principal Investigator
- Jessica Altman
- Status: SUSPENDED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG AG120-C-001
- The purpose of this study is to identify and test the highest dose of AG-120 that can be given safely. We want to find out what effects, good or bad, it has on patients and their disease.
- The use of AG-120 (hereafter, the study drug) in this research study is experimental, which means that it is not approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities around the world for use alone or in combination with any drug. Isocitrate dehydrogenase 1 (IDH1) is a type of protein involved in metabolism or the process of providing the body’s cells with energy. In certain types of diseases such as AML and MDS, an abnormal form of the IDH1 protein is present in the diseased cells. When IDH1 is present in this form, it produces an excess amount of 2-hydroxyglutarate (2-HG), which is a substance that is normally present in cells in low levels. When 2-HG is present in excessive amounts, it may prevent cells from maturing into normal functioning cells and may cause them to become diseased. AG-120 may stop the abnormal IDH1 protein and may reduce 2-HG levels in diseased cells to normal levels.
Some of the eligibility criteria include:
- Participants must have advanced acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Participants must be 18 or older.
- Lab tests must show that the participants have IDH1 gene-mutated disease.
- Description of Treatment
- Participants in this study will take the study drug by mouth in the form of a tablet(s) every day as indicated by the study doctor. The study drug may be continued until the participant's disease gets worse or unacceptable side effects develop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jessica Altman
- A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia
- A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- A Phase IIa, Multicenter, Open-Label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
- A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
- A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
last updated: 05-Jul-15 07:50 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.